(MENAFN- GlobeNewsWire - Nasdaq) Opportunities include precision dosing, automated labs, LC-MS and real-time monitoring. Anti-idiotypic assays and local production are rising, led by Asia-Pacific.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Therapeutic Drug Monitoring Market to Reach $4.09 Billion by 2030 as Precision Dosing Gains Momentum
The global therapeutic drug monitoring market is experiencing rapid expansion, supported by increasing demand for precision medicine, patient-specific dosing, and advanced laboratory diagnostics. The market is projected to grow from $2.41 billion in 2025 to $2.67 billion in 2026, representing a compound annual growth rate (CAGR) of 10.9%.
Historical market growth has been driven by the increasing use of drugs with narrow therapeutic ranges, the expansion of hospital laboratory testing, and broader adoption of immunoassay technologies. The rising prevalence of chronic diseases and continued improvements in analytical instrumentation have also strengthened demand for accurate drug concentration testing across clinical settings.
The therapeutic drug monitoring market is forecast to reach $4.09 billion by 2030, expanding at a CAGR of 11.2%. Growth during the forecast period is expected to be supported by the development of automated diagnostic laboratories, increasing emphasis on individualized treatment, advances in mass spectrometry, and wider adoption of real-time therapeutic monitoring.
Key therapeutic drug monitoring market trends include the increasing use of liquid chromatography-mass spectrometry techniques, growing integration of automated laboratory systems, and expansion of real-time drug-level analysis. Healthcare providers are also placing greater emphasis on precision dosing to improve treatment outcomes, reduce adverse effects, and support more effective management of complex therapies.
The rising use of pharmaceutical drugs is a significant factor supporting market growth. Measuring drug concentrations in the bloodstream enables healthcare professionals to optimize dosage levels, maintain treatment effectiveness, and minimize potential toxicity or side effects. This capability is particularly important for medications with substantial pharmacokinetic variability or limited margins between effective and harmful concentrations.
Demand for drug-related healthcare services is also increasing. In January 2024, the UK Office for Health Improvement & Disparities reported that 12,418 people under the age of 18 engaged with alcohol and drug services between April 2022 and March 2023. This represented a 10% increase from 11,326 cases during the previous year, highlighting the growing need for drug testing, monitoring, and treatment support.
Innovation remains a central focus within the therapeutic drug monitoring industry. Market participants are developing anti-idiotypic antibody technologies designed to improve assay sensitivity and specificity when measuring biologic drug levels and evaluating immune responses. These technologies can support more accurate pharmacokinetic and antidrug-antibody monitoring, helping clinicians make informed dosing decisions.
In June 2024, Bio-Rad Laboratories introduced anti-idiotypic and anti-monomethyl auristatin E antibodies for bioanalytical assays. The products are designed to enhance pharmacokinetic and antidrug-antibody monitoring for antibody-drug conjugates. Improved assay reliability may enable more accurate evaluation of circulating drug levels and patient immune responses, supporting the broader adoption of personalized therapeutic monitoring.
Strategic acquisitions are also reshaping the competitive landscape. In February 2023, Sentinel Diagnostics acquired Eureka S.r.l. for an undisclosed amount. The transaction expanded Sentinel Diagnostics' in vitro diagnostic capabilities and strengthened its ability to offer clinical laboratories a broader portfolio of assays, ranging from high-throughput core laboratory testing to specialized second-level applications.
Eureka's ready-to-use diagnostic kits support high-performance liquid chromatography, gas chromatography, gas chromatography-mass spectrometry, and liquid chromatography-tandem mass spectrometry applications. These capabilities cover specialized clinical chemistry, therapeutic drug monitoring, occupational toxicology, and forensic toxicology, broadening the combined organization's laboratory diagnostics offering.
North America was the largest therapeutic drug monitoring market region in 2025, supported by established healthcare infrastructure, advanced clinical laboratories, and strong adoption of diagnostic technologies. Asia-Pacific is expected to be the fastest-growing region during the forecast period as healthcare investment, laboratory capacity, and access to precision diagnostics continue to increase.
The geographic coverage of the therapeutic drug monitoring market includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Product: Consumables; Equipment; Immunoassay Analyzers; Chromatography And Detectors
2) By Class Of Drug: Antiepileptic Drugs; Antibiotic Drugs; Immunosuppressant Drugs; Antiarrhythmic Drugs; Psychoactive Drugs; Other Drugs
3) By End-user: Hospital Laboratories; Commercial and Private Laboratories; Other End Users
Subsegments:
1) By Consumables: Reagents; Test Kits; Sample Collection Containers; Calibration Standards
2) By Equipment: Analyzers; Incubators; Centrifuges
3) By Immunoassay Analyzers: ELISA Analyzers; Chemiluminescent Immunoassay Analyzers; Radioimmunoassay Analyzers
4) By Chromatography And Detectors: High-Performance Liquid Chromatography (HPLC); Gas Chromatography (GC); Mass Spectrometry (MS)
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment